1. Home
  2. CZNC vs PGEN Comparison

CZNC vs PGEN Comparison

Compare CZNC & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Citizens & Northern Corp

CZNC

Citizens & Northern Corp

N/A

Current Price

$27.44

Market Cap

506.7M

Sector

Finance

ML Signal

N/A

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$4.26

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CZNC
PGEN
Founded
1864
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
506.7M
2.8B
IPO Year
2009
2013

Fundamental Metrics

Financial Performance
Metric
CZNC
PGEN
Price
$27.44
$4.26
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $13.67
AVG Volume (30 Days)
59.6K
★ 7.1M
Earning Date
12-01-2026
11-04-2026
Dividend Yield
★ 4.29%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 1.72
0.12
Revenue
N/A
★ $230,981,000.00
Revenue This Year
$38.42
$2,380.31
Revenue Next Year
$4.97
$84.01
P/E Ratio
★ $16.29
$35.79
Revenue Growth
N/A
N/A
52 Week Low
$19.00
$3.04
52 Week High
$29.25
$8.98

Technical Indicators

Market Signals
Indicator
CZNC
PGEN
Relative Strength Index (RSI) 50.29 32.10
Support Level $25.09 $3.57
Resistance Level $29.25 $4.48
Average True Range (ATR) 0.68 0.45
MACD -0.12 -0.06
Stochastic Oscillator 6.60 9.34

Price Performance

Historical Comparison
CZNC
PGEN

About CZNC Citizens & Northern Corp

Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Share on Social Networks: